494 related articles for article (PubMed ID: 31915932)
1. HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development.
Arab A; Yazdian-Robati R; Behravan J
Arch Immunol Ther Exp (Warsz); 2020 Jan; 68(1):2. PubMed ID: 31915932
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Blockade in Breast Cancer Therapy.
Bu X; Yao Y; Li X
Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
[TBL] [Abstract][Full Text] [Related]
3. HER2-Based Immunotherapy for Breast Cancer.
Cui N; Shi J; Yang C
Cancer Biother Radiopharm; 2018 Jun; 33(5):169-175. PubMed ID: 29874101
[TBL] [Abstract][Full Text] [Related]
4. [Anti-HER2 vaccines: The HER2 immunotargeting future?].
Ladjemi MZ; Jacot W; Pèlegrin A; Navarro-Teulon I
Pathol Biol (Paris); 2011 Jun; 59(3):173-82. PubMed ID: 19481373
[TBL] [Abstract][Full Text] [Related]
5. Developing anti-HER2 vaccines: Breast cancer experience.
Al-Awadhi A; Lee Murray J; Ibrahim NK
Int J Cancer; 2018 Nov; 143(9):2126-2132. PubMed ID: 29693245
[TBL] [Abstract][Full Text] [Related]
6. Anti-HER2 vaccines: new prospects for breast cancer therapy.
Ladjemi MZ; Jacot W; Chardès T; Pèlegrin A; Navarro-Teulon I
Cancer Immunol Immunother; 2010 Sep; 59(9):1295-312. PubMed ID: 20532501
[TBL] [Abstract][Full Text] [Related]
7. Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives.
Milani A; Sangiolo D; Montemurro F; Aglietta M; Valabrega G
Ann Oncol; 2013 Jul; 24(7):1740-1748. PubMed ID: 23585514
[TBL] [Abstract][Full Text] [Related]
8. Proteolytic single hinge cleavage of pertuzumab impairs its Fc effector function and antitumor activity in vitro and in vivo.
Hsiao HC; Fan X; Jordan RE; Zhang N; An Z
Breast Cancer Res; 2018 Jun; 20(1):43. PubMed ID: 29859099
[TBL] [Abstract][Full Text] [Related]
9. The clinical development of vaccines for HER2
Costa RLB; Soliman H; Czerniecki BJ
Cancer Treat Rev; 2017 Dec; 61():107-115. PubMed ID: 29125981
[TBL] [Abstract][Full Text] [Related]
10. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
[TBL] [Abstract][Full Text] [Related]
11. A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors.
Tobias J; Battin C; De Sousa Linhares A; Lebens M; Baier K; Ambroz K; Drinić M; Högler S; Inic-Kanada A; Garner-Spitzer E; Preusser M; Kenner L; Kundi M; Zielinski CC; Steinberger P; Wiedermann U
Front Immunol; 2020; 11():895. PubMed ID: 32528470
[TBL] [Abstract][Full Text] [Related]
12. A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).
Chia S; Bedard PL; Hilton J; Amir E; Gelmon K; Goodwin R; Villa D; Cabanero M; Tu D; Tsao M; Seymour L
Oncologist; 2019 Nov; 24(11):1439-1445. PubMed ID: 31420468
[TBL] [Abstract][Full Text] [Related]
13. Recent progress in immunotherapy of breast cancer targeting the human epidermal growth factor receptor 2 (HER2).
Seyedmirzaei H; Keshavarz-Fathi M; Razi S; Gity M; Rezaei N
J Oncol Pharm Pract; 2021 Jul; 27(5):1235-1244. PubMed ID: 33530866
[TBL] [Abstract][Full Text] [Related]
14. Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine.
Knutson KL; Block MS; Norton N; Erskine CL; Hobday TJ; Dietz AB; Padley D; Gustafson MP; Puglisi-Knutson D; Mangskau TK; Chumsri S; Dueck AC; Karyampudi L; Wilson G; Degnim AC
Clin Cancer Res; 2020 Mar; 26(5):1045-1053. PubMed ID: 31757875
[TBL] [Abstract][Full Text] [Related]
15. Identification of HER2/ neu-derived peptides capable of inducing both cellular and humoral immune responses in HLA-A24 positive breast cancer patients.
Azuma K; Shichijo S; Shomura H; Matsueda S; Fujii T; Itoh K
Breast Cancer Res Treat; 2004 Jul; 86(1):19-29. PubMed ID: 15218358
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of Breast Cancer.
Criscitiello C; Curigliano G
Prog Tumor Res; 2015; 42():30-43. PubMed ID: 26377084
[TBL] [Abstract][Full Text] [Related]
17. Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines.
Wiedermann U; Davis AB; Zielinski CC
Breast Cancer Res Treat; 2013 Feb; 138(1):1-12. PubMed ID: 23340862
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy as a partner for HER2-directed therapies.
Clifton GT; Peoples AGE
Expert Rev Anticancer Ther; 2021 Jul; 21(7):739-746. PubMed ID: 33666116
[No Abstract] [Full Text] [Related]
19. Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium.
Curigliano G; Criscitiello C; Esposito A; Fumagalli L; Gelao L; Locatelli M; Minchella I; Goldhirsch A
Breast; 2013 Aug; 22 Suppl 2():S96-9. PubMed ID: 24074802
[TBL] [Abstract][Full Text] [Related]
20. Immunotargeting of the xCT Cystine/Glutamate Antiporter Potentiates the Efficacy of HER2-Targeted Immunotherapies in Breast Cancer.
Conti L; Bolli E; Di Lorenzo A; Franceschi V; Macchi F; Riccardo F; Ruiu R; Russo L; Quaglino E; Donofrio G; Cavallo F
Cancer Immunol Res; 2020 Aug; 8(8):1039-1053. PubMed ID: 32532810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]